Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2016

24.03.2016 | Urologic Oncology

Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy

verfasst von: Heather J. Chalfin, Jen-Jane Liu, Nilay Gandhi, Zhaoyong Feng, Daniel Johnson, George J. Netto, Charles G. Drake, Noah M. Hahn, Mark P. Schoenberg, Bruce J. Trock, Andrew V. Scott, Steven M. Frank, Trinity J. Bivalacqua

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Perioperative blood transfusion (PBT) has been inconsistently associated with adverse outcomes. Bladder cancer patients are unique as they frequently undergo neoadjuvant chemotherapy (NAC) with resulting immunosuppression, which may be exacerbated by transfusion-related immunomodulation. We examined the effect of leukoreduced PBT on oncologic outcomes and perioperative morbidity in radical cystectomy (RC) patients who received NAC, quantifying exposure with a novel dose-index variable.

Methods

The Johns Hopkins Radical Cystectomy database was queried for patients who had undergone NAC followed by RC from 2010 to 2013. Overall, 119 patients had available PBT and survival data. A multivariable Cox model evaluated risk factors, including pathologic stage, Charlson Comorbidity Index, age, race, year of surgery, surgical margin status, PBT, and preoperative hemoglobin for bladder cancer-specific survival (CSS) and overall survival (OS). Logistic regression models determined factors that were independently associated with perioperative morbidity.

Results

Median follow-up was 7.8 months (range 0.2–41.8), and during follow-up there were 25 deaths and 21 cancer deaths. PBT significantly predicted OS (hazard ratio [HR] 1.26, 95 % confidence interval [CI] 1.07–1.49; p = 0.005), CSS (HR 1.32, 95 % CI 1.11–1.57; p = 0.002), and morbidity (odds ratio [OR] 1.67, 95 % CI 1.26–2.21; p = 0.004) in univariate analyses. In multivariable models, PBT was significantly associated with morbidity (OR 1.77, 95 % CI 1.30–2.39; p = 0.0002), but not OS or CSS. Intraoperative transfusion was associated with decreased OS and CSS, and increased morbidity, whereas postoperative transfusion was only associated with increased morbidity.

Conclusions

Intraoperative blood transfusion was associated with increased perioperative morbidity and worsened OS and CSS in patients undergoing RC who had NAC. Although PBT may be life-saving in certain patients, a restrictive transfusion strategy may improve outcomes.
Literatur
1.
Zurück zum Zitat Dresner SM, Lamb PJ, Shenfine J, et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 2000;26:492–7CrossRefPubMed Dresner SM, Lamb PJ, Shenfine J, et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 2000;26:492–7CrossRefPubMed
2.
Zurück zum Zitat Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 2009;13:1636–42CrossRefPubMed Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 2009;13:1636–42CrossRefPubMed
3.
Zurück zum Zitat Keller SM, Groshen S, Martini N, et al. Blood transfusion and lung cancer recurrence. Cancer. 1988;62:606–10CrossRefPubMed Keller SM, Groshen S, Martini N, et al. Blood transfusion and lung cancer recurrence. Cancer. 1988;62:606–10CrossRefPubMed
4.
Zurück zum Zitat Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–62CrossRefPubMedPubMedCentral Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–62CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Herbert PC, Wells G. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [published erratum appears in N Engl J Med. 1999;340(13):1056] N Engl J Med. 1999;340(6):409–17.CrossRef Herbert PC, Wells G. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [published erratum appears in N Engl J Med. 1999;340(13):1056] N Engl J Med. 1999;340(6):409–17.CrossRef
6.
Zurück zum Zitat Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559–67CrossRefPubMed Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559–67CrossRefPubMed
7.
Zurück zum Zitat Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609–19CrossRefPubMed Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609–19CrossRefPubMed
8.
Zurück zum Zitat 8) Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding [published erratum appears in N Engl J Med. 2013;368(24):2341]. N Engl J Med. 2013;368(1):11–21.CrossRefPubMed 8) Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding [published erratum appears in N Engl J Med. 2013;368(24):2341]. N Engl J Med. 2013;368(1):11–21.CrossRefPubMed
9.
Zurück zum Zitat Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381–91.CrossRefPubMed Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381–91.CrossRefPubMed
10.
Zurück zum Zitat Robertson CS, Hannay HJ, Yamal JM, et al: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014;312(1):36–47CrossRefPubMedPubMedCentral Robertson CS, Hannay HJ, Yamal JM, et al: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014;312(1):36–47CrossRefPubMedPubMedCentral
12.
13.
Zurück zum Zitat Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372–6CrossRefPubMed Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372–6CrossRefPubMed
14.
Zurück zum Zitat Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. Br J Surg. 1991;78:1358–61CrossRefPubMed Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. Br J Surg. 1991;78:1358–61CrossRefPubMed
15.
Zurück zum Zitat Blumberg N. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg. 1998;85:1163–4.PubMed Blumberg N. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg. 1998;85:1163–4.PubMed
16.
Zurück zum Zitat Niegisch G, Albers P, Rabenalt R. Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). Urol Oncol. 2014;32(7):966–74.CrossRefPubMed Niegisch G, Albers P, Rabenalt R. Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). Urol Oncol. 2014;32(7):966–74.CrossRefPubMed
17.
Zurück zum Zitat Morgan TM, Barocas DA, Chang SS, et al. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013;31(6):871–7CrossRefPubMed Morgan TM, Barocas DA, Chang SS, et al. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013;31(6):871–7CrossRefPubMed
18.
Zurück zum Zitat Gierth M, Aziz A, Fritsche HM, et al. The effect of intra- and postoperative allogenic blood transfusion on patients’ survival undergoing radical cystectomy for urothelial carcinoma of the bladder. World J Urol. 2014;32(6):1447–53CrossRefPubMed Gierth M, Aziz A, Fritsche HM, et al. The effect of intra- and postoperative allogenic blood transfusion on patients’ survival undergoing radical cystectomy for urothelial carcinoma of the bladder. World J Urol. 2014;32(6):1447–53CrossRefPubMed
19.
Zurück zum Zitat Kluth LA, Xylinas E, Rieken M, et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014;113(3):393–8CrossRefPubMed Kluth LA, Xylinas E, Rieken M, et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014;113(3):393–8CrossRefPubMed
20.
Zurück zum Zitat Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013;63(5):839–45CrossRefPubMed Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013;63(5):839–45CrossRefPubMed
21.
Zurück zum Zitat Sadeghi N, Badalato GM, Hruby G, et al. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. Can J Urol. 2012;19(5):6443–9PubMed Sadeghi N, Badalato GM, Hruby G, et al. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. Can J Urol. 2012;19(5):6443–9PubMed
22.
Zurück zum Zitat Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48CrossRefPubMed Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48CrossRefPubMed
23.
Zurück zum Zitat Marcato PD, Favaro WJ, Duran N. Cisplatin properties in a nanobiotechnological approach to cancer: a mini-review. Curr Cancer Drug Targets. 2014;14(5):458–76.CrossRefPubMed Marcato PD, Favaro WJ, Duran N. Cisplatin properties in a nanobiotechnological approach to cancer: a mini-review. Curr Cancer Drug Targets. 2014;14(5):458–76.CrossRefPubMed
24.
Zurück zum Zitat Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published erratum appears in N Engl J Med. 2003;349(19):1880]. N Engl J Med. 2003;349(9):859–66.CrossRefPubMed Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published erratum appears in N Engl J Med. 2003;349(19):1880]. N Engl J Med. 2003;349(9):859–66.CrossRefPubMed
25.
Zurück zum Zitat Gandhi NM, Baras A, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol. 2015;33(5):204.e1-7CrossRefPubMedPubMedCentral Gandhi NM, Baras A, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol. 2015;33(5):204.e1-7CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation: the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis. 2013;50:61–8.CrossRefPubMed Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation: the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis. 2013;50:61–8.CrossRefPubMed
27.
Zurück zum Zitat Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth. 2004;51:417–24.CrossRefPubMed Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth. 2004;51:417–24.CrossRefPubMed
28.
Zurück zum Zitat van de Watering L. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47:1946. author reply 7–8.CrossRefPubMed van de Watering L. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47:1946. author reply 7–8.CrossRefPubMed
29.
Zurück zum Zitat Friese RS, Sperry JL, Phelan HA, Gentilello LM. The use of leukoreduced red blood cell products is associated with fewer infectious complications in trauma patients. Am J Surg. 2008;196:56–61.CrossRefPubMed Friese RS, Sperry JL, Phelan HA, Gentilello LM. The use of leukoreduced red blood cell products is associated with fewer infectious complications in trauma patients. Am J Surg. 2008;196:56–61.CrossRefPubMed
30.
Zurück zum Zitat Abel EJ, Linder BJ, et al. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014;66(6):1139–47.CrossRefPubMed Abel EJ, Linder BJ, et al. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014;66(6):1139–47.CrossRefPubMed
31.
Zurück zum Zitat Moschini M, Dell’Oglio P, et al. Effect of allogeneic intraoperative blood transfusion on survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: results from a single high-volume institution. Clin Genitourin Cancer. 2015;13(6):562–7.CrossRefPubMed Moschini M, Dell’Oglio P, et al. Effect of allogeneic intraoperative blood transfusion on survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: results from a single high-volume institution. Clin Genitourin Cancer. 2015;13(6):562–7.CrossRefPubMed
32.
Zurück zum Zitat Eldefrawy A, Soloway MS, Katkoori D, et al. Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: the likelihood of initiation and completion. Indian J Urol. 2012;28(4):424–6.CrossRefPubMedPubMedCentral Eldefrawy A, Soloway MS, Katkoori D, et al. Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: the likelihood of initiation and completion. Indian J Urol. 2012;28(4):424–6.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34(6):1608–16CrossRefPubMed Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34(6):1608–16CrossRefPubMed
35.
Zurück zum Zitat Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology. 2011;114(2):283–92CrossRefPubMed Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology. 2011;114(2):283–92CrossRefPubMed
36.
Zurück zum Zitat Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004;32(1):39–52CrossRefPubMed Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004;32(1):39–52CrossRefPubMed
38.
Zurück zum Zitat Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87CrossRefPubMed Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87CrossRefPubMed
Metadaten
Titel
Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy
verfasst von
Heather J. Chalfin
Jen-Jane Liu
Nilay Gandhi
Zhaoyong Feng
Daniel Johnson
George J. Netto
Charles G. Drake
Noah M. Hahn
Mark P. Schoenberg
Bruce J. Trock
Andrew V. Scott
Steven M. Frank
Trinity J. Bivalacqua
Publikationsdatum
24.03.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5193-4

Weitere Artikel der Ausgabe 8/2016

Annals of Surgical Oncology 8/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.